New hope for hard-to-treat cancers? utidelone tested in advanced solid tumors
NCT ID NCT04911907
First seen Apr 15, 2026 · Last updated Jun 14, 2026 · Updated 11 times
Summary
This study tested the drug utidelone in 126 people with advanced solid tumors (like head and neck, stomach, or ovarian cancer) that had stopped responding to standard treatments or could not be treated with them. The goal was to see if the drug could shrink tumors and how safe it was. The trial had two stages: first, a small group to see which tumor types might respond, then a larger group to get more detailed results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Luhe Hospital, Capital Medical University
Beijing, China
-
Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, China
-
Shanghai East Hospital of Tongji University
Shanghai, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.